Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its novel multiple sclerosis (MS) therapy, Lucid-MS, toward Phase 2 clinical trials following positive Phase 1 safety and tolerability results, according to a BioMedWire editorial highlighting the company's progress.
Lucid-MS is a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy. The editorial notes that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies and is supported by more than a decade of scientific research.
Quantum BioPharma is also advancing a collaboration with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. This could provide a critical tool for assessing treatment efficacy in future trials.
The development of Lucid-MS represents a potential paradigm shift in MS treatment. Current therapies often focus on modulating the immune system to reduce inflammation, but they do not directly address the underlying myelin damage. By targeting myelin protection and repair, Lucid-MS could offer a new approach for patients who do not respond well to existing treatments or who experience progressive forms of the disease.
Multiple sclerosis affects approximately 2.8 million people worldwide, according to the National Multiple Sclerosis Society. While many therapies exist for relapsing-remitting MS, options for progressive MS remain limited. A therapy that directly protects and restores myelin could address a significant unmet medical need.
The company's broader pipeline includes treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. Additionally, Quantum has spun out its OTC product UNBUZZD(TM) to Unbuzzd Wellness Inc., in which it retains a 19.84% stake and royalty payments.
For more information on Quantum BioPharma and its developments, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/iZmx1.
